Sanofi India - Divestiture, Covid-19 Impact Sales; Margins Upbeat: ICICI Direct 
A logo at the Sanofi campus in the Gentilly district (Photographer Nathan Laine/Bloomberg)

Sanofi India - Divestiture, Covid-19 Impact Sales; Margins Upbeat: ICICI Direct 

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Sanofi India Ltd.’s CY20 revenues de-grew 5.5% YoY to Rs 2902 crore mainly due to divestiture of few products to Zentiva (Ankaleshwar slump sale) and Covid-19 impact on certain therapies.

Ebitda margins improved 291 basis points YoY to 24.6% mainly due to lower other expenditure and slightly better gross margins.

Subsequently, Ebitda grew 7.2% YoY to Rs 713 crore. Adjusted profit after tax grew 9.7% YoY to Rs 519 crore.

Note: Results are not comparable YoY due to closure of the Zentiva transaction on May 29, 2020.

Click on the attachment to read the full report:

ICICI Direct Sanofi Company Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.